Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Evaluation of immune responses to adeno-associated virus (AAV)-mediated gene therapies prior to and following dose administration plays a key role in determining therapeutic safety and efficacy. This report describes up to 3 years of immunogenicity data following administration of valoctocogene roxaparvovec (BMN 270), an AAV5-mediated gene therapy encoding human B domain-deleted FVIII (hFVIII-SQ) in a phase 1/2 clinical study of adult males with severe hemophilia A. Patients with pre-existing humoral immunity to AAV5 or with a history of FVIII inhibitors were excluded from the trial. Blood plasma and peripheral blood mononuclear cell (PBMC) samples were collected at regular intervals following dose administration for assessment of humoral and cellular immune responses to both the AAV5 vector and transgene-expressed hFVIII-SQ. The predominant immune response elicited by BMN 270 administration was largely limited to the development of antibodies against the AAV5 capsid that were cross-reactive with other common AAV serotypes. No FVIII inhibitor responses were observed within 3 years following dose administration. In a context of prophylactic or on-demand corticosteroid immunosuppression given after vector infusion, AAV5 and hFVIII-SQ peptide-specific cellular immune responses were intermittently detected by an interferon (IFN)-γ and tumor necrosis factor (TNF)-α FluoroSpot assay, but they were not clearly associated with detrimental safety events or changes in efficacy measures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationLong-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citationAAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Self-citationHigh, K. A., & Roncarolo, M. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1706910 · Cited by 555
Iorio, A., Stonebraker, J. S., Chambost, H., Makris, M., Coffin, D., Herr, C., Germini, F., & for the Data and Demographics Committee of the World Federation of Hemophilia* (2019) · Annals of Internal Medicine · doi:10.7326/m19-1208 · Cited by 462
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
Pasi, K. J., Rangarajan, S., Mitchell, N., Lester, W., Symington, E., Madan, B., Laffan, M., Russell, C. B., Li, M., Pierce, G. F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908490 · Cited by 448
Self-citationGene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
McIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278
Self-citationMendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
George, L. A., Ragni, M. V., Rasko, J. E. J., Raffini, L. J., Samelson-Jones, B. J., Ozelo, M., Hazbon, M., Runowski, A. R., Wellman, J. A., Wachtel, K., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.001 · Cited by 213
Self-citationPien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192
Self-citationMajowicz, A., Nijmeijer, B., Lampen, M. H., Spronck, L., de Haan, M., Petry, H., van Deventer, S. J., Meyer, C., Tangelder, M., & Ferreira, V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.009 · Cited by 126 · cited 3×
“In the Majowicz et al.(24) study, depletion of immunoglobulin G (IgG) did reduce these NAb titers, but AAV5-specific IgG could only be directly detected using an ELISA method in pre-treatment serum samples from patients with higher NAb titers.”
BackgroundMethodInfluentialMingozzi, F., Chen, Y., Murphy, S. L., Edmonson, S. C., Tai, A., Price, S. D., Metzger, M. E., Zhou, S., Wright, J. F., Donahue, R. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.84 · Cited by 112
Self-citationExposure to wild-type AAV drives distinct capsid immunity profiles in humans
Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104 · cited 1×
“Additionally, other studies have demonstrated that TNF-a appears to be the primary cytokine secreted by CD8 T cells in response to the AAV capsid, and these cells could readily be detected in AAV2 seropositive individuals.(38)”
ResultSelf-citationStrategy to detect pre-existing immunity to AAV gene therapy
Falese, L., Sandza, K., Yates, B., Triffault, S., Gangar, S., Long, B., Tsuruda, L., Carter, B., Vettermann, C., Zoog, S. J., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.95 · Cited by 101
Self-citationCalcedo, R., & Wilson, J. M. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.048 · Cited by 77
The impact of pre-existing immunity on the non-clinical pharmacodynamics of AAV5-based gene therapy
Long, B. R., Sandza, K., Holcomb, J., Crockett, L., Hayes, G. M., Arens, J., Fonck, C., Tsuruda, L. S., Schweighardt, B., O’Neill, C. A., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.03.006 · Cited by 75 · cited 3×
“Several previous studies have determined that even comparatively modest titers of neutralizing antibodies specific for AAV capsid are capable of neutralizing transduction and limiting the efficacy of vector-mediated gene therapies in humans and non-human primate species.(23) To avoid any potential safety or efficacy-r…”
BackgroundResultInfluentialSelf-citationManufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines
Kotin, R. M., & Snyder, R. O. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.042 · Cited by 59
Cited by
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
Ozelo, M. C., Mahlangu, J., Pasi, K. J., Giermasz, A., Leavitt, A. D., Laffan, M., Symington, E., Quon, D. V., Wang, J.-D., Peerlinck, K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2113708 · Cited by 417
Self-citationKlamroth, R., Hayes, G., Andreeva, T., Gregg, K., Suzuki, T., Mitha, I. H., Hardesty, B., Shima, M., Pollock, T., Slev, P., et al. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.287 · Cited by 118
Self-citationPrasad, S., Dimmock, D. P., Greenberg, B., Walia, J. S., Sadhu, C., Tavakkoli, F., & Lipshutz, G. S. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.138 · Cited by 81
Gorovits, B., Azadeh, M., Buchlis, G., Harrison, T., Havert, M., Jawa, V., Long, B., McNally, J., Milton, M., Nelson, R., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00628-3 · Cited by 53
Self-citationMuhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., Nixon, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674242 · Cited by 50
Metadata
- Authors
- Long, B. R., Veron, P., Kuranda, K., Hardet, R., Mitchell, N., Hayes, G. M., Wong, W. Y., Lau, K., Li, M., Hock, M. B., Zoog, S. J., Vettermann, C., Mingozzi, F., & Schweighardt, B.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 29
- Issue
- 2
- Pages
- 597-610
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W3111884070
- Cited by
- 76
- References
- 21
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.